Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 67.77% | 71.51% | -294.38% | -187.43% | -245.26% |
| Total Depreciation and Amortization | -10.20% | -14.77% | -13.52% | -12.25% | -9.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -89.12% | -88.26% | 351.73% | 198.12% | 586.25% |
| Change in Net Operating Assets | 141.05% | 135.41% | 66.45% | 64.52% | 41.40% |
| Cash from Operations | -804.55% | 134.07% | 137.50% | 120.69% | 96.86% |
| Capital Expenditure | 3.45% | 1.32% | 10.80% | 17.89% | 42.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | 70.31% | 4.17% | -130.23% | -594.12% | -814.29% |
| Cash from Investing | 34.80% | -61.03% | -95.42% | -130.25% | -51.67% |
| Total Debt Issued | -100.00% | 56.25% | 25.00% | 37.50% | 32.14% |
| Total Debt Repaid | 99.90% | -0.17% | 25.00% | 32.64% | 28.77% |
| Issuance of Common Stock | -39.29% | -39.29% | -44.07% | -44.07% | -95.58% |
| Repurchase of Common Stock | 35.62% | 52.00% | 58.10% | 45.52% | 46.72% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 10.23% | -3,975.00% | -3,975.00% | -3,975.00% | -8,700.00% |
| Cash from Financing | -112.48% | 210.53% | 217.33% | 967.57% | -33.72% |
| Foreign Exchange rate Adjustments | -- | -91.67% | 700.00% | 180.00% | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -204.44% | 289.14% | 643.48% | 235.86% | 81.45% |